Therapeutic Doses of Nonsteroidal Anti-Inflammatory Drugs Inhibit Osteosarcoma MG-63 Osteoblast-Like Cells Maturation, Viability, and Biomineralization Potential

Table 4

(a) ALP activity of MG63-line cell after 24 h of treatment with different NSAIDs at doses of 1 y 10 µM, in non-osteogenic medium, expressed in U/mg of proteins. (b) ALP activity of MG63 line cell after 24 h treatment with different NSAIDs at doses of 1 y 10 µM, in osteogenic medium, expressed in U/mg of proteins.

(a)  

Treatment	Mean	SD^a	𝑃 value
Control	2.67	0.117
Dexketoprofen 1 µM	1.77	0.253	𝟎.𝟎𝟎𝟓^∗
Dexketoprofen 10 µM	1.88	0.207	𝟎.𝟎𝟎𝟓^∗
Ketorolac 1 µM	1.65	0.338	𝟎.𝟎𝟎𝟖^∗
Ketorolac 10 µM	1.79	0.184	𝟎.𝟎𝟎𝟐^∗
Metamizole 1 µM	1.69	0.030	𝟎.𝟎𝟎𝟎^∗
Metamizole 10 µM	1.92	0.083	𝟎.𝟎𝟎𝟏^∗
Acetylsalicylic acid 1 µM	1.77	0.137	𝟎.𝟎𝟎𝟏^∗
Acetylsalicylic acid 10 µM	1.95	0.173	𝟎.𝟎𝟎𝟓^∗

aStandard deviation, ∗significant differences 𝑃<0.05.

(b)  

Treatment	Mean	SD^a	𝑃 value
Control	2.37	0.092
Dexketoprofen 1 µM	2.44	0.293	0.718
Dexketoprofen 10 µM	2.76	0.392	0.165
Ketorolac 1 µM	2.68	1.772	0.029
Ketorolac 10 µM	3.01	3.522	0.216
Metamizole 1 µM	2.43	0.319	0.775
Metamizole 10 µM	3.70	1.602	0.223
Acetylsalicylic acid 1 µM	2.54	1.878	0.446
Acetylsalicylic acid 10 µM	3.31	0.478	0.602

aStandard deviation.